Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY) Revenue
Annual & quarterly revenue history · segment & region breakdown
RLAY · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsRelay Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 53.44% year-over-year from $0.02B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.02B | +$0.01B | +53.44% |
| 2024-12-31 | $0.01B | -$0.02B | -60.83% |
| 2023-12-31 | $0.03B | +$0.02B | +1749.82% |
| 2022-12-31 | $0.00B | -$0.00B | -54.41% |
| 2021-12-31 | $0.00B | -$0.08B | -96.34% |
| 2020-12-31 | $0.08B | +$0.08B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare RLAY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Relay Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Relay Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Relay Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RLAY revenue · 4 questionsRLAY's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 53.44% year-over-year from $0.02B in FY2025.
▸ Source: FMP · Relay Therapeutics, Inc. SEC filings · GAAP · Relay Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026